GlassScriptPhysician profile
Joseph B Noland
NPI 1285681775
$302.43
in general payments reported to CMS, 2019-2025
9 companies · $13.64 in 2025
The $13.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.07 · 2020: $57.58 · 2022: $20.16 · 2023: $77.05 · 2024: $43.93 · 2025: $13.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $105.26 | 2019-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $41.87 | 2019-2023 | Arexvy, Shingrix |
| Novo Nordisk INC | $39.46 | 2022-2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $28.63 | 2024 | Watchman Flx |
| Dexcom, INC. | $23.52 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $19.14 | 2023 | Eliquis |
| Amarin Pharma, INC. | $16.53 | 2019 | |
| Lilly USA, LLC | $15.30 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Noland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.